<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000702</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 005</org_study_id>
    <secondary_id>10981</secondary_id>
    <nct_id>NCT00000702</nct_id>
  </id_info>
  <brief_title>A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection</brief_title>
  <official_title>A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To test whether zidovudine (AZT) is useful as a treatment for the neurologic syndrome called&#xD;
      AIDS dementia complex. To determine how long AZT takes to reach cerebral spinal fluid (CSF),&#xD;
      how long, and at what concentration it is found there.&#xD;
&#xD;
      HIV infection can result in impairment in the function of the brain and spinal cord, leading&#xD;
      to disturbances in the ability to think clearly and in strength and coordination. This&#xD;
      disorder, which has been called the AIDS dementia complex, may be due to a direct effect of&#xD;
      HIV on the nervous system. It is known that AZT does get into the brain to some extent, where&#xD;
      it may reduce growth of HIV. It is hoped that AZT will stabilize or improve the symptoms of&#xD;
      the AIDS dementia complex.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV infection can result in impairment in the function of the brain and spinal cord, leading&#xD;
      to disturbances in the ability to think clearly and in strength and coordination. This&#xD;
      disorder, which has been called the AIDS dementia complex, may be due to a direct effect of&#xD;
      HIV on the nervous system. It is known that AZT does get into the brain to some extent, where&#xD;
      it may reduce growth of HIV. It is hoped that AZT will stabilize or improve the symptoms of&#xD;
      the AIDS dementia complex.&#xD;
&#xD;
      The study is done in 2 stages. In Stage 1, patients are randomized to receive placebo or 1 of&#xD;
      2 doses of AZT. Stage 1 lasts for 4 months. In Stage 2, patients who were initially treated&#xD;
      with placebo are randomized again and all patients receive AZT. Stage 2 lasts an additional&#xD;
      12 months, during which time there are periodic medical and neurologic evaluations. Before&#xD;
      beginning treatment, all patients have a lumbar puncture and a computerized tomographic (CT)&#xD;
      scan of the brain. The lumbar puncture is repeated twice during and once at the end of Stage&#xD;
      1; the CT scan is also repeated at the end of Stage 1. Patients receiving AZT in either stage&#xD;
      1 or Stage 2 are seen by their physicians every week for the first 4 weeks and every other&#xD;
      week thereafter for the first 4 months of receiving the drug. After 4 months, patients are&#xD;
      seen by their physicians at 4 to 12 week intervals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">August 1990</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>315</enrollment>
  <condition>AIDS Dementia Complex</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aspirin, in modest doses.&#xD;
&#xD;
          -  Ibuprofen, in modest doses.&#xD;
&#xD;
          -  Maintenance antibiotic therapy posttherapy for an AIDS-defining opportunistic&#xD;
             infection.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Blood transfusion if cardiovascular status is compromised.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Active substance abuse.&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions will be excluded:&#xD;
&#xD;
          -  Concurrent or previous central nervous system infections or neoplasms.&#xD;
&#xD;
          -  Active AIDS-defining opportunistic infection.&#xD;
&#xD;
          -  Severe premorbid psychiatric illness.&#xD;
&#xD;
          -  Confounding neurological disease.&#xD;
&#xD;
          -  Concurrent neoplasms.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Maintenance methadone or naltrexone.&#xD;
&#xD;
          -  Acetaminophen.&#xD;
&#xD;
          -  Mood- or central nervous system-altering drugs.&#xD;
&#xD;
          -  Zidovudine for Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Rifampin or derivatives.&#xD;
&#xD;
          -  Drugs with antiretroviral activity.&#xD;
&#xD;
          -  Experimental agents.&#xD;
&#xD;
        The following patients will be excluded from the study:&#xD;
&#xD;
          -  Patients requiring ongoing therapy for an AIDS-defining opportunistic infection.&#xD;
&#xD;
          -  Patients with a history of Mycobacterium avium intracellulare infection.&#xD;
&#xD;
          -  Patients with a history of Pneumocystis carinii pneumonia infection.&#xD;
&#xD;
          -  Patients with a daily temperature of 38 degrees C or more for 1 month.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Excluded within 14 days of study entry:&#xD;
&#xD;
          -  Systemic anti-infectives.&#xD;
&#xD;
          -  Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Immunomodulators and biologic response modifiers.&#xD;
&#xD;
          -  Any investigational agent.&#xD;
&#xD;
          -  Cytotoxic chemotherapy for Kaposi's sarcoma.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Patients must demonstrate the following clinical and laboratory findings:&#xD;
&#xD;
          -  No currently active AIDS-defining opportunistic infections.&#xD;
&#xD;
          -  One negative blood culture for Mycobacterium avium intracellulare within 4-6 weeks&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Constitutionally well without persistent fever.&#xD;
&#xD;
          -  Less than 25 Kaposi's sarcoma lesions and less than 10 new lesions during the 30 days&#xD;
             prior to study entry. Patients may have stable or indolently progressive mucocutaneous&#xD;
             Kaposi's sarcoma.&#xD;
&#xD;
          -  Characteristic clinical symptoms and signs of AIDS dementia complex.&#xD;
&#xD;
          -  Abnormalities on 2 or more of 7 neuropsychological motor tests in the Neurological&#xD;
             Screening Battery.&#xD;
&#xD;
          -  Estimated premorbid IQ equal to or greater than 70 (+ or - 5), which is consistent&#xD;
             with completion of sixth grade.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R Price</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California / San Diego Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921036325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Univ School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charity Hosp / Tulane Univ Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State Univ Med Ctr / Tulane Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard (Massachusetts Gen Hosp)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Med Ctr</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Municipal Hosp Ctr/Jacobi Med Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jack Weiler Hosp / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10465</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY / Erie County Med Ctr at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hosp Ctr at Elmhurst / Mount Sinai Hosp</name>
      <address>
        <city>Elmhurst</city>
        <state>New York</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr / Peter Krueger Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hosp / New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Sloan - Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, Hirsch MS, Schaerf FW, Fischl MA, Kieburtz K, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol. 1993 Apr;33(4):343-9. doi: 10.1002/ana.410330403.</citation>
    <PMID>8489204</PMID>
  </reference>
  <reference>
    <citation>Price RW, Koch MA, Sidtis JJ, Feinberg J, Collier A, Kennedy C, Singer E, Price S. Zidovudine (AZT) treatment of the AIDS dementia complex (ADC): results of a placebo-controlled, multicentered therapeutic trial. Int Conf AIDS. 1989 Jun 4-9;5:407 (abstract no WBP331)</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS Dementia Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>AIDS Dementia Complex</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

